Evidence map›Paper›PMID 34962431›Full record

ArticlePharmaceutical biology2022

Suchilactone inhibits the growth of acute myeloid leukaemia by inactivating SHP2.

Jingjing Wu, Yuan Deng, Xin Zhang, Jingjing Ma, Xinqi Zheng, Yue Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutical biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jingjing WuDepartment of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Yuan DengDepartment of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Xin ZhangDepartment of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Jingjing MaDepartment of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Xinqi ZhengDepartment of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Yue ChenDepartment of Hematology, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Nanjing Medical University · CNHuaian First People’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextSuchilactone, a lignan compound extracted from

objectiveTo investigate the antitumor effect of suchilactone and its mechanism in AML. MATERIALS AND

methodsThe effects of suchilactone on cell growth were detected by CCK-8 and flow cytometry. Network pharmacology was conducted to explore target of suchilactone. Gene expression was detected by western blot and RT-PCR. SHI-1 cells (1 × 10

resultsSuchilactone exerted an effective inhibition on the growth of SHI-1 cells with IC DISCUSSION AND

conclusionsOur study is the first to demonstrate suchilactone inhibits AML growth, suggesting that suchilactone is a candidate drug for the treatment of AML.

Indexed as

Antineoplastic Agents, PhytogenicGeraniaceaeLeukemia, Myeloid, AcuteProtein Tyrosine Phosphatase, Non-Receptor Type 11AnimalsApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugFemaleHumansLignansMiceMice, Inbred BALB CMice, SCIDNetwork PharmacologyAntineoplastic Agents, PhytogenicLignansProtein Tyrosine Phosphatase, Non-Receptor Type 11PTPN11 protein, humansuchilactoneERK pathway proliferation apoptosisMonsonia angustifolianetwork pharmacology

Identifiers

PMID34962431
PMCPMC8725822
OpenAlexW4200241506

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.